The Palm

Palm Therapeutics is a San Diego-based biotechnology company specializing in the development of small molecule drugs that target protein palmitoylation, a critical post-translational modification. The company utilizes its proprietary PalmReader platform, a high-throughput screening technology, to identify inhibitors for previously undruggable targets. Palm's lead program is a selective NRAS palmitoylation inhibitor designed to treat cancers with activating NRAS mutations, including melanoma and acute myeloid leukemia. Beyond oncology, the company is exploring the potential of its platform in rare diseases and other therapeutic areas where palmitoylation plays a key role in disease progression.